Retatrutide Pen Specifications & Research Handling

What Is the Retatrutide Pen Format?

The retatrutide pen is a prefilled liquid research format with a nominal 30mg content and 300-click device scale. Unlike a lyophilised vial, it does not require a reconstitution step. The nominal scale is a product specification; current lot and device documentation control the actual dispensing calibration and compatible laboratory accessories.

This guide documents hardware identity, composition, storage and evidence sources. It does not translate published trial schedules into product-use instructions or provide priming, injection, accessory-selection or mg-to-click guidance.

Published Phase 2 and Phase 3 trials used protocol-controlled administration by study teams.^[1][3] Those clinical procedures are reported as historical evidence and do not establish a handling protocol for research-use material.

What Are the Pen Specifications?

The retatrutide 30mg pen is a prefilled research device. The specification rows below separate nominal composition and scale from the documentation that controls laboratory handling.

The device scale is a product specification, not an administration schedule. Do not infer a use protocol from the nominal content or click count.

What Controls Research Handling?

The pen is a prefilled research format. Handling, dispensing calibration, compatible laboratory accessories, storage limits, and disposal must follow the current lot documentation, device documentation, and an authorised institutional laboratory SOP. Remy Peptides does not provide priming, needle-selection, injection, administration, or personal-use instructions.

Published retatrutide trials used protocol-controlled subcutaneous administration by study teams. That historical fact is reported as clinical evidence only and does not establish a use procedure for a research-use product.

Which Sources Control the Device Record?

Use the current product specification and batch documentation for composition and verification, and the current lot/device documentation plus institutional SOPs for laboratory handling. Published clinical-trial schedules belong to the cited study records and are not converted here into product clicks, quantities, or administration steps.

How Does a Pen Differ from a Lyophilised Vial?

A prefilled pen and a lyophilised vial are different laboratory formats. The pen is a sealed liquid device; the vial is a dry research material whose preparation and handling depend on its batch documentation and the institution's SOP. This page does not rank formats by personal convenience or translate either format into administration instructions.

ZPHC-labelled pen references documented in the wider market include a Retatrutide AQ 30mg pen and a Retatrutide 60mg dual-chamber pen. Lyophilised ZPHC references appear separately as a 15mg vial and as 10mg, 20mg, 40mg, 60mg and 120mg multi-vial kits. Format labels of this kind carry no analytical weight on their own — the evidence boundary is set by whichever batch certificate is attached to the material, not by the device it arrives in.

How Should a Retatrutide Pen Be Stored?

Knowing how to store a retatrutide pen protects peptide integrity and keeps research results consistent. Retatrutide degrades when exposed to heat, light, or repeated freeze-thaw cycles, so the cold chain matters from the point of receipt onward.

Before First Use

• Store at 2–8°C (standard refrigerator temperature)
• Do not freeze — freezing can damage the peptide structure and the pen mechanism
• Keep in original packaging to protect from light
• Store upright if possible

After First Use

• Always return to refrigerated storage (2–8°C) after each use — do not store at room temperature
• Do not expose to temperatures above 30°C
• Avoid direct sunlight or prolonged UV exposure
• Follow the current device documentation and institutional SOP for closure and storage

So what happens if a retatrutide pen gets warm? Brief room-temperature exposure during use is expected, but sustained heat above 30°C or direct sun accelerates degradation — a pen left in a hot car or shipped without a cold chain should be treated as compromised. For underlying peptide degradation kinetics, see the peptide stability and storage guide. In hot climates such as the UAE — where ambient temperatures regularly exceed 45°C — temperature-controlled transport and refrigerated storage are non-negotiable. The Retatrutide UAE page carries the documented UAE format record, and the broader UAE research compound map indexes every compound covered in this library.